AAAAAA

   
Results: 1-15 |
Results: 15
Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial
Authors: Foudraine, NA Jurriaans, S Weverling, GJ Burger, DM Hoetelmans, RMW Roos, MTL Maas, J Miedema, F Reiss, P Portegies, P de Wolf, F Lange, JMA
Citation: Na. Foudraine et al., Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial, ANTIVIR TH, 6(1), 2001, pp. 55-62
Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection
Authors: Enting, RH Prins, JM Jurriaans, S Brinkman, K Portegies, P Lange, JMA
Citation: Rh. Enting et al., Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection, CLIN INF D, 32(7), 2001, pp. 1095-1099
Kaposi's sarcoma and human herpesvirus 8 infection do not protect HIV-1 infected homosexual men from AIDS dementia complex
Authors: Renwick, N Weverling, GJ Halaby, T Portegies, P Bakker, M Schulz, TF Goudsmit, J
Citation: N. Renwick et al., Kaposi's sarcoma and human herpesvirus 8 infection do not protect HIV-1 infected homosexual men from AIDS dementia complex, AIDS, 15(16), 2001, pp. 2165-2169
Diagnostic investigation of patients with chronic polyneuropathy: evaluation of a clinical guideline
Authors: Rosenberg, NR Portegies, P de Visser, M Vermeulen, M
Citation: Nr. Rosenberg et al., Diagnostic investigation of patients with chronic polyneuropathy: evaluation of a clinical guideline, J NE NE PSY, 71(2), 2001, pp. 205-209
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy
Authors: Gisolf, EH van Praag, RME Jurriaans, S Portegies, P Goudsmit, J Danner, SA Lange, JMA Prins, JM
Citation: Eh. Gisolf et al., Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy, J ACQ IMM D, 25(5), 2000, pp. 426-433
Epstein-Barr virus and the nervous system
Authors: Portegies, P Corssmit, N
Citation: P. Portegies et N. Corssmit, Epstein-Barr virus and the nervous system, CURR OP NEU, 13(3), 2000, pp. 301-304
Cytarabine and highly active antiretroviral therapy in HIV-related progressive multifocal leukoencephalopathy
Authors: Enting, RH Portegies, P
Citation: Rh. Enting et P. Portegies, Cytarabine and highly active antiretroviral therapy in HIV-related progressive multifocal leukoencephalopathy, J NEUROL, 247(2), 2000, pp. 134-138
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir
Authors: van Praag, RME Weverling, GJ Portegies, P Jurriaans, S Zhou, XJ Turner-Foisy, ML Sommadossi, JP Burger, DM Lange, JMA Hoetelmans, RMW Prins, JM
Citation: Rme. Van Praag et al., Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir, AIDS, 14(9), 2000, pp. 1187-1194
Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine
Authors: Gisolf, EH Enting, RH Jurriaans, S de Wolf, F van der Ende, ME Hoetelmans, RMW Portegies, P Danner, SA
Citation: Eh. Gisolf et al., Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine, AIDS, 14(11), 2000, pp. 1583-1589
Cerebrospinal fluid beta 2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine
Authors: Enting, RH Foudraine, NA Lange, JMA Jurriaans, S van der Poll, T Weverling, GJ Portegies, P
Citation: Rh. Enting et al., Cerebrospinal fluid beta 2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine, J NEUROIMM, 102(2), 2000, pp. 216-221
AIDS dementia complex
Authors: Portegies, P Enting, RH
Citation: P. Portegies et Rh. Enting, AIDS dementia complex, IMMUNOL MED, 28, 2000, pp. 209-220
Nitric oxide synthase expression and apoptotic cell death in brains of AIDS and AIDS dementia patients
Authors: Vincent, VAM De Groot, CJA Lucassen, PJ Portegies, P Troost, D Tilders, FJH Van Dam, AM
Citation: Vam. Vincent et al., Nitric oxide synthase expression and apoptotic cell death in brains of AIDS and AIDS dementia patients, AIDS, 13(3), 1999, pp. 317-326
Overexpression of nerve growth factor and basic fibroblast growth factor in AIDS dementia complex
Authors: Boven, LA Middel, J Portegies, P Verhoef, J Jansen, GH Nottet, HSLM
Citation: La. Boven et al., Overexpression of nerve growth factor and basic fibroblast growth factor in AIDS dementia complex, J NEUROIMM, 97(1-2), 1999, pp. 154-162
Reduced prevalence of the CCR5 Delta 32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex
Authors: van Rij, RP Portegies, P Hallaby, T Lange, JMA Visser, J Husman, AMD van't Wout, AB Schuitemaker, H
Citation: Rp. Van Rij et al., Reduced prevalence of the CCR5 Delta 32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex, J INFEC DIS, 180(3), 1999, pp. 854-857
Increased peroxynitrite activity in AIDS dementia complex: Implications for the neuropathogenesis of HIV-1 infection
Authors: Boven, LA Gomes, L Hery, C Gray, F Verhoef, J Portegies, P Tardieu, M Nottet, HSLM
Citation: La. Boven et al., Increased peroxynitrite activity in AIDS dementia complex: Implications for the neuropathogenesis of HIV-1 infection, J IMMUNOL, 162(7), 1999, pp. 4319-4327
Risultati: 1-15 |